The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015

Global Burden of Disease Liver Cancer Collaboration, Tomi Akinyemiju, Semaw Abera, Muktar Ahmed, Noore Alam, Mulubirhan Assefa Alemayohu, Christine Allen, Rajaa Al-Raddadi, Nelson Alvis-Guzman, Yaw Amoako, Al Artaman, Tadesse Awoke Ayele, Aleksandra Barac, Isabela Bensenor, Adugnaw Berhane, Zulfiqar Bhutta, Jacqueline Castillo-Rivas, Abdulaal Chitheer, Jee-Young Choi, Benjamin Cowie, Lalit Dandona, Rakhi Dandona, Subhojit Dey, Daniel Dicker, Huyen Phuc, Donatus U. Ekwueme, Maysaa El Sayed Zaki, Florian Fischer, Thomas Fürst, Jamie Hancock, Simon I. Hay, Peter Hotez, Sun Ha Jee, Amir Kasaeian, Yousef Khader, Young-Ho Khang, Anil Kumar, Michael Kutz, Heidi Larson, Alan Lopez, Raimundas Lunevicius, Reza Malekzadeh, Colm McAlinden, Toni Meier, Walter Mendoza, Ali Mokdad, Maziar Moradi-Lakeh, Gabriele Nagel, Quyen Nguyen, Grant Nguyen, Felix Ogbo, George Patton, David M. Pereira, Farshad Pourmalek, Mostafa Qorbani, Amir Radfar, Gholamreza Roshandel, Joshua A Salomon, Juan Sanabria, Benn Sartorius, Maheswar Satpathy, Monika Sawhney, Sadaf Sepanlou, Katya Shackelford, Hirbo Shore, Jiandong Sun, Desalegn Tadese Mengistu, Roman Topór-Mądry, Bach Tran, Kingsley Nnanna Ukwaja, Vasiliy Vlassov, Stein Emil Vollset, Theo Vos, Tolassa Wakayo, Elisabete Weiderpass, Andrea Werdecker, Naohiro Yonemoto, Mustafa Younis, Chuanhua Yu, Zoubida Zaidi, Liguo Zhu, Christopher J. L. Murray, Mohsen Naghavi, Christina Fitzmaurice, Global Burden of Disease Liver Cancer Collaboration, Tomi Akinyemiju, Semaw Abera, Muktar Ahmed, Noore Alam, Mulubirhan Assefa Alemayohu, Christine Allen, Rajaa Al-Raddadi, Nelson Alvis-Guzman, Yaw Amoako, Al Artaman, Tadesse Awoke Ayele, Aleksandra Barac, Isabela Bensenor, Adugnaw Berhane, Zulfiqar Bhutta, Jacqueline Castillo-Rivas, Abdulaal Chitheer, Jee-Young Choi, Benjamin Cowie, Lalit Dandona, Rakhi Dandona, Subhojit Dey, Daniel Dicker, Huyen Phuc, Donatus U. Ekwueme, Maysaa El Sayed Zaki, Florian Fischer, Thomas Fürst, Jamie Hancock, Simon I. Hay, Peter Hotez, Sun Ha Jee, Amir Kasaeian, Yousef Khader, Young-Ho Khang, Anil Kumar, Michael Kutz, Heidi Larson, Alan Lopez, Raimundas Lunevicius, Reza Malekzadeh, Colm McAlinden, Toni Meier, Walter Mendoza, Ali Mokdad, Maziar Moradi-Lakeh, Gabriele Nagel, Quyen Nguyen, Grant Nguyen, Felix Ogbo, George Patton, David M. Pereira, Farshad Pourmalek, Mostafa Qorbani, Amir Radfar, Gholamreza Roshandel, Joshua A Salomon, Juan Sanabria, Benn Sartorius, Maheswar Satpathy, Monika Sawhney, Sadaf Sepanlou, Katya Shackelford, Hirbo Shore, Jiandong Sun, Desalegn Tadese Mengistu, Roman Topór-Mądry, Bach Tran, Kingsley Nnanna Ukwaja, Vasiliy Vlassov, Stein Emil Vollset, Theo Vos, Tolassa Wakayo, Elisabete Weiderpass, Andrea Werdecker, Naohiro Yonemoto, Mustafa Younis, Chuanhua Yu, Zoubida Zaidi, Liguo Zhu, Christopher J. L. Murray, Mohsen Naghavi, Christina Fitzmaurice

Abstract

Importance: Liver cancer is among the leading causes of cancer deaths globally. The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use.

Objective: To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an “other” group that encompasses residual causes.

Design, Settings, and Participants: Mortality was estimated using vital registration and cancer registry data in an ensemble modeling approach. Single-cause mortality estimates were adjusted for all-cause mortality. Incidence was derived from mortality estimates and the mortality-to-incidence ratio. Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified. Years of life lost were calculated by multiplying each death by a standard life expectancy. Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival. Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs). DALYs were the sum of years of life lost and YLDs.

Main Outcomes and Measures: Liver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year.

Results: There were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs. Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and −8% to changing age-specific incidence rates. The male-to-female ratio for age-standardized liver cancer mortality was 2.8. Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies.

Conclusions and Relevance: Liver cancer is among the leading causes of cancer deaths in many countries. Causes of liver cancer differ widely among populations. Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use. In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden. The GBD study can be used to guide these prevention efforts.

Conflict of interest statement

Conflict of Interest Disclosures: Prof Larson reports that her research group has received funding from GlaxoSmithKline (GSK) and Merck to convene research symposia, as well as funding from GSK for advising on vaccine hesitancy issues. Prof Larson also reports that she has served on the Merck Vaccines Strategic Advisory Board. Dr Mendoza reports that he is currently the Program Analyst at the United Nations Population Fund Country Office in Peru, an institution that does not necessarily endorse this study. No other disclosures are reported.

Figures

Figure 1.. Relative Changes in Age-Standardized Liver…
Figure 1.. Relative Changes in Age-Standardized Liver Cancer Mortality Between 1990 and 2015 for Both Sexes in 195 Countries and Territories
ATG indicates Antigua and Barbuda; BRB, Barbados; COM, Comoros; DMA, Dominica; FJI, Fiji; FSM, Federated States of Micronesia; GRD, Grenada; KIR, Kiribati; LCA, Saint Lucia; MDV, Maldives; MHL, Marshall Islands; MLT, Malta; MUS, Mauritius; TLS, Timor-Leste; TON, Tonga; TTO, Trinidad and Tobago; SGP, Singapore; SLB, Soloman Islands; SYC, Seychelles; VCT, Saint Vincent and the Grenadines; VUT, Vanuatu; and WSM, Samoa (formerly Western Samoa).
Figure 2.. Contribution of Hepatitis B, Hepatitis…
Figure 2.. Contribution of Hepatitis B, Hepatitis C, Alcohol, and Other Causes on Absolute Liver Cancer Deaths, Both Sexes, Globally and by Region, 2015
SDI indicates sociodemographic index.

References

    1. GBD 2015 Mortality and Causes of Death Collaborators . Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-1544. doi:10.1016/S0140-6736(16)31012-1
    1. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139(7):1534-1545. doi:10.1002/ijc.30211
    1. Chuang S-C, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett. 2009;286(1):9-14. doi:10.1016/j.canlet.2008.10.040
    1. International Agency for Research on Cancer . Known causes and prevention of human cancer by organ site. August 2016. . Accessed August 7, 2017.
    1. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group . Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794-798. doi:10.1056/NEJMsr1606602
    1. World Health Organization . Global health sector strategy on viral hepatitis 2016-2021. June 2016. . Accessed September 9, 2016.
    1. World Health Organization . Global action plan for the prevention and control of noncommunicable diseases 2013-2020. 2013. .
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386. doi:10.1002/ijc.29210
    1. Ryerson AB, Eheman CR, Altekruse SF, et al. . Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312-1337. doi:10.1002/cncr.29936
    1. Fan J-H, Wang J-B, Jiang Y, et al. . Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev. 2013;14(12):7251-7256.
    1. Asim M, Sarma MP, Kar P. Etiological and molecular profile of hepatocellular cancer from India. Int J Cancer. 2013;133(2):437-445. doi:10.1002/ijc.27993
    1. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609-e616. doi:10.1016/S2214-109X(16)30143-7
    1. Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. . Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122(11):1757-1765. doi:10.1002/cncr.29971
    1. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190-1200. doi:10.1002/hep.27969
    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-1602.
    1. Global Burden of Disease Cancer Collaboration . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-548. doi:10.1001/jamaoncol.2016.5688
    1. Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012;10(1):1. doi:10.1186/1478-7954-10-1
    1. Flaxman AD, Vos T, Murray C. An Integrative Metaregression Framework for Descriptive Epidemiology. Seattle, WA: University of Washington Press; 2015.
    1. Salomon JA, Vos T, Hogan DR, et al. . Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-2143. doi:10.1016/S0140-6736(12)61680-8
    1. Das Gupta P. Standardization and Decomposition of Rates: a User’s Manual. Washington, DC: US Department of Commerce, Economics and Statistics Administration, Bureau of the Census; 1993.
    1. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753-770. doi:10.1016/j.bpg.2014.08.007
    1. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2362-2368. doi:10.1158/1055-9965.EPI-11-0643
    1. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15(2):223-243, vii-x. doi:10.1016/j.cld.2011.03.006
    1. Nayagam S, Thursz M, Sicuri E, et al. . Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16(12):1399-1408. doi:10.1016/S1473-3099(16)30204-3
    1. Ward JW, Mermin JH. Simple, effective, but out of reach? public health implications of HCV drugs. N Engl J Med. 2015;373(27):2678-2680. doi:10.1056/NEJMe1513245
    1. Edwards DJ, Coppens DG, Prasad TL, Rook LA, Iyer JK. Access to hepatitis C medicines. Bull World Health Organ. 2015;93(11):799-805. doi:10.2471/BLT.15.157784
    1. Guirguis J, Chhatwal J, Dasarathy J, et al. . Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. Alcohol Clin Exp Res. 2015;39(11):2085-2094. doi:10.1111/acer.12887
    1. World Health Organization . Global strategy to reduce harmful use of alcohol. WHO. . Accessed December 10, 2016.
    1. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118(6):818-824. doi:10.1289/ehp.0901388
    1. Fürst T, Keiser J, Utzinger J. Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(3):210-221. doi:10.1016/S1473-3099(11)70294-8
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431
    1. Chen J, Zhang Y, Chen Y, Ding L. Incidence trend of liver cancer: an analysis of 40 years data from Qidong population-based cancer registry. Zhongguo Zhong Liu. 2014;23:621-628.
    1. Zheng R, Zuo T, Zeng H, Zhang S, Chen W. [Mortality and survival analysis of liver cancer in China]. Zhonghua Zhong Liu Za Zhi. 2015;37(9):697-702.
    1. Sun Z, Chen T, Thorgeirsson SS, et al. . Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34(8):1800-1805. doi:10.1093/carcin/bgt007
    1. Hao XS, Wang PP, Chen KX, et al. . Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev. 2003;12(4):273-279. doi:10.1097/01.cej.0000082607.47188.86
    1. Chimed T, Sandagdorj T, Znaor A, et al. . Cancer incidence and cancer control in Mongolia: results from the National Cancer Registry 2008-2012. Int J Cancer. 2017;140(2):302-309. doi:10.1002/ijc.30463
    1. Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. The increasing burden of imported chronic hepatitis B--United States, 1974-2008. PLoS One. 2011;6(12):e27717. doi:10.1371/journal.pone.0027717
    1. Cohen C, Holmberg SD, McMahon BJ, et al. . Is chronic hepatitis B being undertreated in the United States? J Viral Hepat. 2011;18(6):377-383. doi:10.1111/j.1365-2893.2010.01401.x
    1. National Comprehensive Cancer Network . NCCN Guidelines Hepatocellular Carcinoma. Version 2.2016. 2016. . Accessed April 15, 2017.
    1. Llovet JM, Ricci S, Mazzaferro V, et al. ; SHARP Investigators Study Group . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. doi:10.1056/NEJMoa0708857
    1. Connell LC, Harding JJ, Abou-Alfa GK. Advanced hepatocellular cancer: the current state of future research. Curr Treat Options Oncol. 2016;17(8):43. doi:10.1007/s11864-016-0415-3
    1. Polednak AP. Using cancer registries to assess the accuracy of primary liver or intrahepatic bile duct cancer as the underlying cause of death, 1999-2010. J Registry Manag. 2013;40(4):168-175.
    1. Percy C, Ries LG, Van Holten VD. The accuracy of liver cancer as the underlying cause of death on death certificates. Public Health Rep. 1990;105(4):361-367.
    1. Ahern RM, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray CJ. Improving the public health utility of global cardiovascular mortality data: the rise of ischemic heart disease. Popul Health Metr. 2011;9(1):8. doi:10.1186/1478-7954-9-8
    1. Chang I-C, Huang S-F, Chen P-J, et al. . The hepatitis viral status in patients with hepatocellular carcinoma: a study of 3843 patients from Taiwan Liver Cancer Network. Medicine (Baltimore). 2016;95(15):e3284. doi:10.1097/MD.0000000000003284

Source: PubMed

3
Prenumerera